Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone-Refractory Prostate Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT06826768
What this trial is testing

A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC

Who this might be right for
Prostate Cancer
M.D. Anderson Cancer Center 60
Testing effectiveness (Phase 2)Study completedNCT03454750
What this trial is testing

Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC)

Who this might be right for
Metastatic Castration Resistant Prostate Cancer68Ga-PSMA PET/CT Positive
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 143
Not applicableStudy completedNCT03223597
What this trial is testing

Registry of Treatment Outcomes of Symptomatic Metastasized Castration Resistant Prostate Cancer Treated With Radium-223

Who this might be right for
Prostate Cancer MetastaticBone Metastases
The Netherlands Cancer Institute 300
Testing effectiveness (Phase 2)Study completedNCT03939689
What this trial is testing

I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).

Who this might be right for
Metastatic Prostate CancerCastration-resistant Prostate CancerProstatic Neoplasm+2 more
Progenics Pharmaceuticals, Inc. 120
Large-scale testing (Phase 3)Study completedNCT01193244
What this trial is testing

Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Millennium Pharmaceuticals, Inc. 1,560
Testing effectiveness (Phase 2)Study completedNCT01867333
What this trial is testing

Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer

Who this might be right for
Prostate Cancer
National Cancer Institute (NCI) 57
Early research (Phase 1)Ended earlyNCT05369000
What this trial is testing

Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
Lava Therapeutics 96
Early research (Phase 1)Study completedNCT02532114
What this trial is testing

Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer

Who this might be right for
Castration Levels of TestosteroneCastration-Resistant Prostate CarcinomaMetastatic Prostate Carcinoma+2 more
University of Washington 5
Large-scale testing (Phase 3)Study completedNCT00004071
What this trial is testing

Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer

Who this might be right for
Prostate Cancer
Pfizer
Testing effectiveness (Phase 2)Ended earlyNCT04179864
What this trial is testing

Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer

Who this might be right for
Metastatic Prostate CancerMetastatic Castration-resistant Prostate Cancer
Epizyme, Inc. 102
Testing effectiveness (Phase 2)UnknownNCT00024414
What this trial is testing

DHA-Paclitaxel in Treating Patients With Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
Theradex
Testing effectiveness (Phase 2)Study completedNCT03658447
What this trial is testing

PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
Peter MacCallum Cancer Centre, Australia 37
Testing effectiveness (Phase 2)Study completedNCT00976755
What this trial is testing

Everolimus as First-Line Therapy in Treating Patients With Prostate Cancer

Who this might be right for
Prostate Cancer
Swiss Cancer Institute 37
Early research (Phase 1)Looking for participantsNCT07503808
What this trial is testing

IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

Who this might be right for
Esophageal Squamous Cell CarcinomaHigh Grade Serous Ovarian CancerHead and Neck Squamous Cell Carcinoma+5 more
IDEAYA Biosciences 150
Testing effectiveness (Phase 2)Looking for participantsNCT06610825
What this trial is testing

Castrate Resistant Prostate Cancer Enhertu Therapy

Who this might be right for
Prostate Cancer MetastaticProstate CancerCRPC
Washington D.C. Veterans Affairs Medical Center 60
Not applicableStudy completedNCT02398526
What this trial is testing

Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases

Who this might be right for
Castration-Resistant Prostatic Cancer
Bayer 363
Not applicableEnded earlyNCT04436120
What this trial is testing

Treatment Resistance Following Anti-cancer Therapies

Who this might be right for
Disease Progression
Pfizer 38
Early research (Phase 1)Study completedNCT04477512
What this trial is testing

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Who this might be right for
Metastatic Hormone Refractory Prostate Cancer
Washington University School of Medicine 18
Testing effectiveness (Phase 2)Study completedNCT01393730
What this trial is testing

Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Mary-Ellen Taplin, MD 40
Early research (Phase 1)Study completedNCT04148937
What this trial is testing

The CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer

Who this might be right for
Advanced Cancer
Eli Lilly and Company 52
Next Page